Kairos Pharma KAPA
NYSE KAPA
$0.55 +0.01 (+1.05%)
As of: Oct 23, 2026 · 3:59 PM EDT

Kairos Pharma (KAPA) Return on Equity [ROE] (2024 - 2025)

Updated

Kairos Pharma (KAPA) posted Return on Equity [ROE] of -97.99% for FY2025, up 78.28 percentage points from -176.28% in FY2024.

Analysis

Kairos Pharma (KAPA) Return on Equity [ROE] (2024 - 2025) Analysis & Trends

  • Business Quant data shows KAPA's Return on Equity [ROE] at -176.28% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn 19.33%
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn -
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn 7.21%
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn 31.52%
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 21.39%
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn 83.75%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -18.38%
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 4.97%
10 Kairos Pharma 10.50 Mn -1.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -68.93%
Mar 31, 2025 -56.05%
Dec 31, 2024 -58.66%
Sep 30, 2024 -597.05%
API Access

Kairos Pharma Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=KAPA&period=max&api_key=YOUR_API_KEY